Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Scott Miller

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Gynecologic Oncology|June 8, 2002
Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group studyJohn H Edmonson, John A Blessing, Jonathan A Cosin, et al.
Gynecologic Oncology|February 10, 2004
Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group studyFranco M Muggia, John A Blessing, Michael Method, et al.
Gynecologic Oncology|October 7, 2009
A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic OncologyDavid Scott Miller, John A Blessing, Richard D Drake, et al.
Gynecologic Oncology|February 22, 2005
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group studyAgustin A Garcia, John A Blessing, Heinz-Josef Lenz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology groupDavid Scott Miller, John A Blessing, Lois M Ramondetta, et al.
Gynecologic Oncology Reports|September 21, 2020
Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgerySally Mullany, David Scott Miller, Katina Robison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2011
Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group studyRaymond J Osborne, Virginia Filiaci, Julian C Schink, et al.
Archives of Gynecology and Obstetrics|October 16, 2014
Surgical and systemic management of endometrial cancer: an international surveyChristina Fotopoulou, Robert Kraetschell, Sean Dowdy, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2023
Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's ChoiceDomenica Lorusso, Nicoletta Colombo, Antonio Casado Herraez, et al.
Gynecologic Oncology|January 24, 2025
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258Aine Clements, Danielle Enserro, Kyle C Strickland, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Gynecologic Oncology|June 8, 2002
Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group studyJohn H Edmonson, John A Blessing, Jonathan A Cosin, et al.
Gynecologic Oncology|February 10, 2004
Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group studyFranco M Muggia, John A Blessing, Michael Method, et al.
Gynecologic Oncology|October 7, 2009
A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic OncologyDavid Scott Miller, John A Blessing, Richard D Drake, et al.
Gynecologic Oncology|February 22, 2005
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group studyAgustin A Garcia, John A Blessing, Heinz-Josef Lenz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology groupDavid Scott Miller, John A Blessing, Lois M Ramondetta, et al.
Gynecologic Oncology Reports|September 21, 2020
Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgerySally Mullany, David Scott Miller, Katina Robison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2011
Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group studyRaymond J Osborne, Virginia Filiaci, Julian C Schink, et al.
Archives of Gynecology and Obstetrics|October 16, 2014
Surgical and systemic management of endometrial cancer: an international surveyChristina Fotopoulou, Robert Kraetschell, Sean Dowdy, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2023
Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's ChoiceDomenica Lorusso, Nicoletta Colombo, Antonio Casado Herraez, et al.
Gynecologic Oncology|January 24, 2025
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258Aine Clements, Danielle Enserro, Kyle C Strickland, et al.
Pageof 4